Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool November 13, 2009 Brian Orelli	Abbott: Brave or Stupid? Abbott Labs announces the acquisition of PanGenetics' pain drug PG110, which is still in phase 1 trials.
The Motley Fool June 18, 2010 Denise Gellene	San Diego's Neurocrine Biosciences Scores Second Big Deal in Two Days The San Diego biotech agreed to grant German drug maker Boehringer Ingelheim and signed a pact with Abbott Labs.
The Motley Fool November 6, 2006 Brian Lawler	Neurocrine's Big Headache Another clinical trial means a steep drop in share price, but the biopharmaceutical's not dead yet. Investors, take note.
The Motley Fool March 10, 2010 Brian Orelli	You Paid How Much for That? Abbott steps up where Biogen Idec wouldn't.
The Motley Fool September 24, 2010 Brian Orelli	Good Deal? Bad Deal? Hard to Tell. Investors are in the dark on Abbott Labs' license of Reata Pharmaceuticals' kidney failure drug bardoxolone for $450 million up front.
The Motley Fool October 20, 2010 Matt Koppenheffer	Neurocrine Biosciences Shares Popped: What You Need to Know Shares of biotech Neurocrine Biosciences were up more than 10% in intraday trading on higher-than-average volume.
The Motley Fool November 13, 2006 Brian Lawler	Kos' Swan Song The drug company releases what will probably be its last earnings announcement before a buyout by Abbot Labs. Investors, take note.
The Motley Fool November 8, 2010 Brian Orelli	No Sticking Point Here: Pfizer's Potential Blockbuster Works Translating successful phase 2 results into a positive phase 3 trial can require a bit of luck, especially for a disease such as rheumatoid arthritis where the outcomes are somewhat subjective.
The Motley Fool January 12, 2005 Charly Travers	Forget Earnings; Think R&D Look at the big picture to find biotech companies with the most promise.
The Motley Fool January 21, 2010 Brian Orelli	Here's That Critical Merck Info You Missed Announcing clinical trial failures in a FAQ? Really?
The Motley Fool June 23, 2006 Stephen D. Simpson	Neurocrine Biosciences: From Bad to Worse Pfizer's departure is a serious, though not fatal, blow to the biotech. While this story may yet have a happy ending, there's going to be a lot of nervous waiting between now and then. Investors, take note.
The Motley Fool April 26, 2007 Tom Taulli	Phase Forward's False Funk Ignore its stagnant shares -- new deals should continue this company's growth.
The Motley Fool April 19, 2004 Charly Travers	4 Promising Biotech IPOs Several recently gone-public biotechs boast surprisingly interesting drug pipelines. From drugs for hepatitis to hopeful cancer treatments, watch out for these four biotech debutantes. If trials go smoothly, they may be the next up-and-coming stocks in the industry.
Fast Company December 2009 Erica Westly	The Price of Winning FDA Approval Approval for a new drug or medical treatment requires extensive -- and expensive -- human trials for safety and effectiveness.
The Motley Fool May 15, 2006 Brian Gorman	AstraZeneca's Peer-Pressure Purchase The drug company seems to be paying a lot for Cambridge Antibody. Perhaps AstraZeneca didn't want to be left behind as its rivals bought up biotech technology -- but in its haste, it may be paying a steep price for what it's getting. Investors, take note.
The Motley Fool June 29, 2010 Brian Orelli	Redeploying Capital? Investors Hope So. Selling a business unit won't help Abbott Labs diversify.
The Motley Fool August 28, 2009 Brian Orelli	Abbott Signs Up Another One Abbott announces that it has set up a partnership with Pfizer to run tests on Pfizer's new drug.
The Motley Fool July 18, 2006 Brian Lawler	Neurocrine's Tale of Woe After a couple of tough months, Neurocrine released its second-quarter results. This may be a great stock to own -- if you have the stomach to tolerate the risk.
The Motley Fool May 24, 2007 Mike Havrilla	A New Era at AEterna A strong balance sheet and a pair of promising products underlie optimism for the biopharmaceutical's future prospects.
The Motley Fool August 19, 2010 Brian Orelli	High Risk, High Reward. At Least It Was Cheap! Biogen licenses a drug to treat ALS.
The Motley Fool June 15, 2007 Brian Lawler	Neurocrine Moves Ahead Neurocrine resubmits a marketing application for its lead drug. Investors, take note.
The Motley Fool January 24, 2007 Brian Lawler	Neurocrine in the Green 2006 wasn't kind to the drug developer, but whatever happens with indiplon, Neurocrine's management deserves kudos for keeping investors well informed on the status of the drug and where the company stands as far as timelines go.
The Motley Fool June 23, 2010 Kris Eddy	Drugmakers Finally Recognize the Next Big Opportunity Drug companies seem to be increasing efforts to address female health problems.
The Motley Fool June 12, 2009 Brian Orelli	Where Good Drugs Go to Die Human Genome Sciences has the potential to pop if Benlysta's phase 3 trials are a success, but tread lightly, history is not on their side.
The Motley Fool September 28, 2006 Brian Lawler	Myriad Moves Forward The biotech's new cancer candidate passes phase 1 trials. Investors should take note, and make room for Myriad on their radar screens.
The Motley Fool October 8, 2007 Charly Travers	Scanning 4 Biotechs There are major events set for the following biotech companies during this quarter. Investors, take note: BioMarin Pharmaceutical... Exelixis... Neurocrine Biosciences... Pain Therapeutics...
The Motley Fool August 29, 2006 Brian Lawler	More Good News for Rituxan Genentech and Biogen Idec's drug shows positive results against multiple sclerosis. Investors, take note.
The Motley Fool April 13, 2011 Brian Orelli	Abbott's Potential Billion-Dollar Problem Abbott's Humira forms antibodies in nearly a quarter of patients.
The Motley Fool July 14, 2009 Brian Orelli	Diagnosing a Personalized Partnership Abbott and Glaxo hook up on diagnostics.
The Motley Fool December 14, 2007 Brian Orelli	An Overnight Three-Bagger It's not often you see stocks triple in one day, but that's what Rigel Pharmaceuticals did. You might be surprised, however, as to why. Investors, take note.
The Motley Fool May 8, 2007 Brian Lawler	Neurocrine Is Waking Up After being put to sleep for much of 2006 following an unexpected FDA smackdown on its lead drug, indiplon, shares of the biopharma have boosted over 50% higher versus its lows last year.
The Motley Fool June 26, 2009 Brian Orelli	The $16 Billion Market That Could Make You Rich A large market just waiting to be taken over.
The Motley Fool September 26, 2007 Brian Lawler	Following the Fallen Biotech Class of 2006 Let's take a look a list of the biggest development stage drugmaker disasters from 2006 and how the tiny drug developers have fared since they announced their clinical trial or regulatory failures.
The Motley Fool September 28, 2009 Rick Aristotle Munarriz	Abbott Labs Looks Less Lopsided Abbott Labs' $6.6 billion purchase of Solvay's pharmaceuticals business is just what the doctor ordered.
Investment Advisor December 2005 Greg B. Scott	Buying The Future Prudent investing in biotechnology can offer great returns for clients. It's also the wave of the future. Armed with a basic understanding of the dynamics of the industry and the valuation inflection points, intelligent investors can make significant returns.
The Motley Fool June 29, 2007 Brian Orelli	The Phase 2 Blues Drug developer Cytokinetics disappoints investors with failed clinical trials.
The Motley Fool August 28, 2006 Brian Lawler	The Commandments of Biotech Investing Since long-term successful biotech investing requires accurate risk assessment, you must be aware of the risk you're taking on. Just as with any prospective investment, if you diversify your biotech holdings, you can somewhat mitigate these various risks.
The Motley Fool August 2, 2004 Charly Travers	What's a Drug Worth? The value of small biotech companies is in their investigational drug programs.
The Motley Fool July 9, 2004 Phil Wohl	Abbott Labs Concocts Strong Q2 The drug maker reports earnings as expected and refines its third-quarter guidance.
The Motley Fool March 4, 2004 Brian Gorman	Biotech Is Back Biotech financing is on a roll. But before you jump into the sector, learn some lessons from the past. Companies that enter the market earlier in the boom are better positioned than those that start later, and it's best to choose firms with late-stage drug candidates.
The Motley Fool December 14, 2005 Stephen D. Simpson	Arena Fattens Wallets Positive phase 2 data sends the biotech's stock up big and raises hopes of a blockbuster.
The Motley Fool January 26, 2005 Stephen D. Simpson	The Pipeline to Biotech Success Looking at drug R&D is the best way to begin assessing biotech companies as possible investment opportunities.
The Motley Fool June 29, 2007 Brian Lawler	Genentech's All Good The biotech's latest partnership deal is nothing to worry about. Investors, take note.
The Motley Fool September 5, 2006 Brian Lawler	Neurocrine Wakes Up Indiplon The biotech company announces new drug delays. Investors, take note.
The Motley Fool December 14, 2007 Brian Lawler	FDA Knocks Neurocrine a Knuckle Sandwich The FDA clobbers drugmaker Neurocrine with another delay.
The Motley Fool October 31, 2006 Brian Lawler	A Look Inside the Biotech Haunted House Even after being warned of the risks, if you're still brave enough to come inside the biotech haunted house, realize that there are surprises. For example, the FDA will spook investors with calls for more clinical trials on drugs that appear to be a lock for approval.
The Motley Fool October 11, 2010 Brian Orelli	What Meridia's Demise Means for Arena, VIVUS, and Orexigen Safety first ... and second ... and third...
The Motley Fool June 22, 2011 Brian Orelli	In-Licensing to the Rescue Abbott's latest deal could help shore things up.
The Motley Fool March 29, 2010 Brian Orelli	Look for Companies That Strike First Head-to-head trials, whether they're run by companies or by third parties, can be scary. But the way to make big money is by selling drugs that offer superior benefits, so investors should welcome the onslaught of upcoming comparative trial data.
The Motley Fool February 6, 2008 Brian Lawler	Neurocrine on the Upswing? Neurocrine Bioscience releases year-end numbers, and updates investors on the status of its top drugs.